Futures slip, bank earnings ahead, Powell to speak - what’s moving markets
Investing.com -- Enzymatica AB has named Holger Lembrér as its new Chief Financial Officer, with his start date set for no later than April 2026. Lembrér will join the company’s executive management team.
Lembrér brings significant experience as a CFO and finance executive from international and publicly listed companies, primarily in the MedTech, Pharma and industrial sectors. He most recently worked as CFO at Boule Diagnostics, where he managed the Group’s finance function.
Before joining Boule Diagnostics, Lembrér served as CFO at Oncopeptides and held various senior positions at ASSA ABLOY, including CFO for the Senior Care business area and Investor Relations Officer at the Group level. He started his career as an auditor at EY.
Bengt Baron, Chairman of the Board of Enzymatica AB, said: "Holger combines solid financial expertise with strong business acumen and an international outlook. His experience from growth journeys in listed companies makes him a valuable addition to Enzymatica’s management team, which together with the incoming CEO will drive the company’s international expansion."
Lembrér expressed his enthusiasm about joining the company: "I look forward to joining Enzymatica in an exciting phase. The company has significant commercial potential and a dedicated team. Together with the incoming CEO, I aim to help strengthen global commercialization and build sustainable, profitable growth."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.